Aberdeen Group plc Purchases 100,403 Shares of Kenvue Inc. $KVUE

Key Points

• Aberdeen Group plc increased its holdings in Kenvue Inc. by 15.1%, acquiring an additional 100,403 shares, bringing its total to 766,450 shares valued at approximately $16 million.
• Kenvue recently declared a quarterly dividend of $0.2075, up from the previous $0.21, resulting in a 5.1% dividend yield for investors.
• Despite a quarterly earnings report showing a slight beat in EPS at $0.29, Kenvue's revenue declined by 4.0% year-over-year, prompting analysts to lower their price targets on the stock.

Aberdeen Group plc lifted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 15.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 766,450 shares of the company's stock after purchasing an additional 100,403 shares during the quarter. Aberdeen Group plc's holdings in Kenvue were worth $16,015,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in KVUE. Pittenger & Anderson Inc. bought a new stake in shares of Kenvue in the first quarter worth about $30,000. Trust Co. of Vermont increased its holdings in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock worth $33,000 after purchasing an additional 1,150 shares during the last quarter. TruNorth Capital Management LLC bought a new stake in shares of Kenvue in the first quarter worth about $36,000. Truvestments Capital LLC bought a new stake in shares of Kenvue in the first quarter worth about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd increased its stake in Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after acquiring an additional 1,287 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 0.3%

Shares of NYSE KVUE opened at $16.18 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The firm has a market capitalization of $31.04 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 2.33 and a beta of 0.72. The stock has a 50 day moving average price of $18.92 and a 200 day moving average price of $21.22. Kenvue Inc. has a 52-week low of $15.47 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.Kenvue's quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.1%. Kenvue's dividend payout ratio (DPR) is presently 112.16%.

Analysts Set New Price Targets

Several brokerages have weighed in on KVUE. Bank of America reduced their price objective on Kenvue from $25.00 to $21.00 and set a "buy" rating on the stock in a research note on Wednesday, October 8th. Rothschild Redb raised Kenvue from a "hold" rating to a "strong-buy" rating in a research note on Friday, September 26th. Evercore ISI reduced their price objective on Kenvue from $23.00 to $18.00 and set an "in-line" rating on the stock in a research note on Tuesday, September 23rd. Canaccord Genuity Group reduced their price objective on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Kenvue in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $21.18.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.